PriceTargets.com logo

NASDAQ:ETNB - 89bio Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $41.43
  • Forecasted Upside: 1,343.50 %
  • Number of Analysts: 7
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 6 Buy Ratings
  • 1 Strong Buy Ratings
$2.87 As of 05/23/2022 01:00 AM ET
▼ -0.25 (-8.01%)

This chart shows the closing price for ETNB by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New 89bio Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ETNB and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ETNB

Analyst Price Target is $41.43
▲ +1,343.50% Upside Potential
This price target is based on 7 analysts offering 12 month price targets for 89bio in the last 3 months. The average price target is $41.43, with a high forecast of $0.00 and a low forecast of $0.00. The average price target represents a 1,343.50% upside from the last price of $2.87.

This chart shows the closing price for ETNB for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 7 investment analysts is to buy stock in 89bio. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 1 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/29/2020
  • 1 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/27/2021
  • 1 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/28/2021
  • 1 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/26/2021
  • 1 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/24/2021
  • 1 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/22/2022
  • 1 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/23/2022
  • 1 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/23/2022

Latest Recommendations

  • 1 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/17/2022Piper SandlerLower Price TargetOverweight$54.00 ➝ $19.00Low
5/13/2022OppenheimerLower Price Target$49.00 ➝ $40.00Medium
5/12/2022HC WainwrightLower Price Target$46.00 ➝ $29.00Medium
5/12/2022Cantor FitzgeraldLower Price Target$41.00 ➝ $27.00High
5/12/2022Raymond JamesUpgradeOutperform ➝ Strong-Buy$33.00 ➝ $12.00High
3/25/2022SVB LeerinkLower Price TargetOutperform$62.00 ➝ $50.00High
12/20/2021HC WainwrightInitiated CoverageBuy$46.00High
11/12/2021Royal Bank of CanadaLower Price TargetOutperform$46.00 ➝ $42.00Medium
10/26/2021Cantor FitzgeraldReiterated RatingOverweight$58.00 ➝ $49.00High
10/18/2021Cantor FitzgeraldReiterated RatingOverweightLow
8/15/2021SVB LeerinkReiterated RatingBuy$62.00High
8/13/2021Royal Bank of CanadaLower Price TargetOutperform$48.00 ➝ $46.00Low
8/13/2021Raymond JamesLower Price TargetOutperform$35.00 ➝ $33.00Low
7/29/2021BTIG ResearchInitiated CoverageBuy$60.00High
6/13/2021SVB LeerinkReiterated RatingBuyMedium
5/25/2021Raymond JamesDowngradeStrong-Buy ➝ Outperform$65.00 ➝ $35.00High
5/19/2021SVB LeerinkReiterated RatingBuy$62.00Medium
4/21/2021Cantor FitzgeraldInitiated CoverageOverweight$58.00High
3/25/2021Chardan CapitalBoost Price TargetBuy$92.00 ➝ $95.00High
3/23/2021SVB LeerinkBoost Price TargetOutperform$56.00 ➝ $62.00High
3/18/2021OppenheimerReiterated RatingBuy$60.00High
11/11/2020SVB LeerinkBoost Price TargetOutperform$51.00 ➝ $56.00High
10/19/2020Raymond JamesInitiated CoverageStrong-Buy$65.00High
9/25/2020Bank of AmericaUpgradeNeutral ➝ Buy$43.00High
9/15/2020BTIG ResearchBoost Price TargetBuy$51.00 ➝ $58.00High
9/15/2020Chardan CapitalBoost Price TargetBuy$59.00 ➝ $95.00High
8/13/2020Chardan CapitalBoost Price TargetBuy$58.00 ➝ $59.00Low
7/30/2020Piper SandlerInitiated CoverageOverweight$54.00High
7/23/2020BTIG ResearchInitiated CoverageBuyLow
7/7/2020Chardan CapitalInitiated CoverageBuy$58.00High
5/19/2020OppenheimerReiterated RatingBuy$60.00High
1/2/2020SVB LeerinkReiterated RatingOutperformLow
12/9/2019SVB LeerinkInitiated CoverageOutperform$55.00High
12/9/2019OppenheimerInitiated CoverageOutperform$60.00High
12/9/2019Royal Bank of CanadaInitiated CoverageOutperform$36.00High
12/9/2019Bank of AmericaInitiated CoverageNeutral$33.00High
(Data available from 5/24/2017 forward)

News Sentiment Rating

0.11 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 3 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/26/2021
  • 2 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/25/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/25/2021
  • 0 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
1/24/2022
  • 3 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
2/23/2022
  • 2 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/25/2022
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/24/2022
  • 0 very positive mentions
  • 15 positive mentions
  • 4 negative mentions
  • 0 very negative mentions
Mentions as of
5/24/2022

Current Sentiment

  • 0 very positive mentions
  • 15 positive mentions
  • 4 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

  • No very positive mentions tracked during this time.
89bio logo
89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also intends to develop pegozafermin for the treatment of severe hypertriglyceridemia. 89bio, Inc. was incorporated in 2018 and is headquartered in San Francisco, California.
Read More

Today's Range

Now: $2.87
Low: $2.75
High: $3.33

50 Day Range

MA: $3.12
Low: $2.09
High: $4.17

52 Week Range

Now: $2.87
Low: $2.00
High: $22.31

Volume

231,359 shs

Average Volume

203,581 shs

Market Capitalization

$58.41 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.82

Frequently Asked Questions

What sell-side analysts currently cover shares of 89bio?

The following Wall Street research analysts have issued stock ratings on 89bio in the last twelve months: BTIG Research, Cantor Fitzgerald, HC Wainwright, Oppenheimer Holdings Inc., Piper Sandler, Raymond James, Royal Bank of Canada, SVB Leerink LLC, and Zacks Investment Research.
View the latest analyst ratings for ETNB.

What is the current price target for 89bio?

0 Wall Street analysts have set twelve-month price targets for 89bio in the last year. Their average twelve-month price target is $41.43, suggesting a possible upside of 1,343.5%.
View the latest price targets for ETNB.

What is the current consensus analyst rating for 89bio?

89bio currently has 6 buy ratings and 1 strong buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe ETNB will outperform the market and that investors should add to their positions of 89bio.
View the latest ratings for ETNB.

How do I contact 89bio's investor relations team?

89bio's physical mailing address is 142 SANSOME STREET SECOND FLOOR, SAN FRANCISCO CA, 94104. The company's listed phone number is 415-500-4614 and its investor relations email address is [email protected] The official website for 89bio is www.89bio.com. Learn More about contacing 89bio investor relations.